|

Novel Augmentation of DAOIB and Antioxidant for Early Dementia

RECRUITINGPhase 2Sponsored by Chang Gung Memorial Hospital
Actively Recruiting
PhasePhase 2
SponsorChang Gung Memorial Hospital
Started2024-06-19
Est. completion2027-05
Eligibility
Age50 Years – 90 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT06467539

Summary

Previous studies found that some NMDA-enhancing agents were able to improve cognitive function of patients with early-phase dementia. In addition, several drugs with antioxidant properties have been tested in clinical trials for the treatment of dementia too. Whether combined treatment of an NMDA-enhancing agent and a drug with antioxidant property can be better than an NMDA-enhancing agent alone deserves study.

Eligibility

Age: 50 Years – 90 YearsHealthy volunteers accepted
Inclusion Criteria:

* Clinical diagnosis of Alzheimer's disease or mild cognitive impairment
* MMSE between 10-26
* CDR 1 or 0.5

Exclusion Criteria:

* Hachinski Ischemic Score \> 4
* Substance abuse/dependence
* Parkinson disease, epilepsy, dementia with psychotic features
* Major depressive disorder
* Major physical illnesses
* Severe visual or hearing impairment

Conditions3

Alzheimer DiseaseAlzheimer's DiseaseMild Cognitive Impairment

Browse More Trials

Alzheimer's Disease trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.